Omeprazole : Calcitonin stimulation test for the diagnosis follow-up and family screening in medullary thyroid carcinoma

Medullary thyroid carcinoma (MTC) occurs sporadically but may also be inherited as part of the multiple endocrine neoplasia (MEN) type 2 syndrome. Screening of the patients and first degree relatives annually with basal and provocative tests for serum immunoreactive calcitonin (CT) levels is essenti...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 1997-03, Vol.82 (3), p.897-899
Main Authors: MURAT FAIK ERDOGAN, GÜLLÜ, S, BASKAL, N, ALI RIZA UYSAL, KAMEL, N, ERDOGAN, G
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Calcitonin - blood
Carcinoma, Medullary - diagnosis
Endocrinopathies
Female
Follow-Up Studies
Gastrins - blood
Humans
Immunoradiometric Assay
Male
Malignant tumors
Medical sciences
Middle Aged
Multiple Endocrine Neoplasia Type 2a - blood
Omeprazole
Pentagastrin
Reference Values
Thyroid Neoplasms - diagnosis
Thyroid. Thyroid axis (diseases)
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Medullary thyroid carcinoma (MTC) occurs sporadically but may also be inherited as part of the multiple endocrine neoplasia (MEN) type 2 syndrome. Screening of the patients and first degree relatives annually with basal and provocative tests for serum immunoreactive calcitonin (CT) levels is essential and enables potentially curative disease. Pentagastrin and calcium are the usual provocative agents used worldwide. We used endogenous gastrin (GT) release achieved by omeprazole, 20 mg b.i.d., to stimulate CT in 9 MTC, in 3 MEN 2A family members, and in 50 healthy control subjects. A steady and significant increase both in GT and CT levels was achieved in 9 MTC patients and 3 of the 14 family members tested, whereas in healthy controls the CT increase stimulated by GT was insignificant. Preliminary results showed that this new, safe, cheap, and outpatient-basis test can be used in MTC diagnosis, follow-up, and screening.
ISSN:0021-972X
1945-7197
DOI:10.1210/jc.82.3.897